HC Wainwright & Co. Affirms Buy Rating for Alto Neuroscience, Keeps $10 Price Target Intact
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 18 2025
0mins
Should l Buy ANRO?
Source: Benzinga
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and intelligence.
Market Winning Tool: Traders utilize Benzinga Pro's resources to enhance their trading success in the stock market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ANRO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ANRO
Wall Street analysts forecast ANRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANRO is 32.86 USD with a low forecast of 16.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 14.110
Low
16.00
Averages
32.86
High
50.00
Current: 14.110
Low
16.00
Averages
32.86
High
50.00
About ANRO
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on redefining psychiatry by leveraging neurobiology to develop personalized and effective treatment options. The Company's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Healthcare Stocks Surge in After-Hours Trading
- Acumen Pharmaceuticals Surge: Acumen Pharmaceuticals, Inc. (ABOS) advanced 8.09% in after-hours trading to close at $2.94, adding $0.22, indicating strong investor confidence in its growth prospects.
- Fulgent Genetics Rise: Fulgent Genetics, Inc. (FLGT) rose 5.98% to $28.90 in after-hours trading, gaining $1.63, reflecting market optimism regarding its business outlook.
- Fractyl Health Growth: Fractyl Health, Inc. (GUTS) climbed 5.19% to $2.23 after hours, up $0.11, suggesting that its potential in the biotech sector is being recognized by the market.
- Coeptis Therapeutics Increase: Coeptis Therapeutics Holdings, Inc. (COEP) added 4.14% to finish at $13.85, gaining $0.55 in after-hours trading, demonstrating investor support for its strategic direction.
See More
Alto Neuroscience and Others Under Investigation for Shareholder Claims
- Shareholder Lawsuit Investigation: Johnson Fistel, PLLP is investigating shareholder claims against Alto Neuroscience (NYSE: ANRO) and others, alleging breaches of fiduciary duty that could lead to corporate governance reforms and return of funds.
- False Statements Allegations: Alto Neuroscience is accused of making false statements regarding the efficacy of its lead drug ALTO-100, resulting in investor losses when the truth was revealed, negatively impacting the company's reputation and stock price.
- Anticompetitive Pricing Practices: Atkore Inc. (NYSE: ATKR) faces a securities class action lawsuit alleging executives failed to disclose anticompetitive pricing practices related to PVC pipe products, which may lead to legal risks and diminished shareholder trust.
- Safety Risks Concealment: Fly-E Group (NASDAQ: FLYE) is accused of downplaying safety risks associated with its lithium battery technology in electric mobility products, leading to a stock price decline and harming investor interests, affecting the company's future growth prospects.
See More
Alto Neuroscience Secures Patent for ALTO-207, Enhancing Depression Treatment Potential
- Patent Protection Strengthened: Alto has secured U.S. Patent Number 12,521,374 covering methods for treating depression with ALTO-207, which protects the use of ondansetron to mitigate pramipexole-related side effects, enabling patients to achieve higher doses for antidepressant benefits, significantly enhancing ALTO-207's market competitiveness.
- Clinical Trial Success: In a randomized, placebo-controlled Phase 2a clinical trial involving 32 patients with depression, ALTO-207 demonstrated significantly improved MADRS scores, with patients reaching a mean dose of 4.1mg per day, indicating the drug's efficacy and tolerability in treating treatment-resistant depression.
- Intellectual Property Strategy: The issuance of this patent further solidifies Alto's intellectual property portfolio, expected to extend commercial opportunities for ALTO-207 into the mid-2040s, enhancing the company's long-term growth potential in the mental health sector.
- Innovative Treatment Platform: Alto's Precision Psychiatry Platform aims to provide personalized treatment options by analyzing EEG, neurocognitive assessments, and wearable data, driving the company's innovative advancements in depression and other mental health conditions.
See More
Alto Neuroscience Secures Patent for ALTO-207, Protecting Key Treatment Method Until Mid-2040s
- Patent Protection Extended: Alto Neuroscience announced the issuance of U.S. Patent Number 12,521,374 covering methods for treating depression with ALTO-207, expected to provide protection into the mid-2040s, thus offering the company a long-term commercial opportunity in the treatment of treatment-resistant depression.
- Innovative Combination Therapy: ALTO-207 combines pramipexole and ondansetron to mitigate side effects associated with pramipexole, enabling patients to achieve higher doses for more significant antidepressant effects, addressing the urgent market demand for new therapies.
- Clinical Trial Success: In a randomized, placebo-controlled Phase 2a trial involving 32 patients with depression, ALTO-207 demonstrated significant efficacy, with patients reaching a mean dose of 4.1mg per day and an adverse event rate similar to placebo, indicating good tolerability.
- Strategic Value Enhancement: CEO Amit Etkin emphasized that a robust intellectual property foundation is critical for advancing precision treatments, and this patent issuance not only reflects the novelty of ALTO-207 but also strengthens the company's competitive position in the mental health market.
See More
Alto Neuroscience Grants 150,000 Stock Options at $12.80 to New Employee
- Option Grant: On December 2, 2025, Alto Neuroscience granted a new employee an option to purchase 150,000 shares at an exercise price of $12.80, equal to the closing price on the grant date, aimed at attracting talent and enhancing employee loyalty.
- Long-term Incentive Structure: The option has a 10-year term and vests over four years, with 25% vesting on the first anniversary and the remainder in equal monthly installments, ensuring continued employee contribution during their service.
- Compliance Assurance: This grant complies with NYSE Listed Company Manual Rule 303A.08, ensuring the company's adherence to regulations while attracting and retaining key talent with transparency.
- Strategic Implications: By implementing this incentive plan, Alto not only enhances its attractiveness but also demonstrates confidence in future growth, aiming to reshape the field of psychiatry through innovative drug development.
See More
Johnson Fistel, PLLP Launches Investigation for Long-Term Shareholders of Alto Neuroscience, Inc. (ANRO), Atkore Inc. (ATKR), Dow Inc. (DOW), and Fly-E Group, Inc. (FLYE)
Investigation of Shareholder Claims: Johnson Fistel, PLLP is investigating potential claims for shareholders of Alto Neuroscience, Atkore Inc., Dow Inc., and Fly-E Group, Inc. regarding alleged breaches of fiduciary duty by their officers and directors.
Allegations Against Alto Neuroscience: A federal securities class action claims that Alto Neuroscience misrepresented the effectiveness of its drug candidate ALTO-100, leading to investor losses when the truth about its efficacy was revealed.
Concerns with Atkore Inc.: A pending class action alleges that Atkore participated in an anticompetitive price-fixing scheme that inflated prices for PVC pipe products, resulting in financial performance issues once scrutiny increased.
Issues with Dow Inc. and Fly-E Group: Dow is accused of misleading investors about its dividend sustainability amid macroeconomic pressures, while Fly-E faces allegations of downplaying safety issues related to its lithium-battery technology, both leading to significant stock price declines.
See More
Healthcare Stocks Surge in After-Hours Trading
- Acumen Pharmaceuticals Surge: Acumen Pharmaceuticals, Inc. (ABOS) advanced 8.09% in after-hours trading to close at $2.94, adding $0.22, indicating strong investor confidence in its growth prospects.
- Fulgent Genetics Rise: Fulgent Genetics, Inc. (FLGT) rose 5.98% to $28.90 in after-hours trading, gaining $1.63, reflecting market optimism regarding its business outlook.
- Fractyl Health Growth: Fractyl Health, Inc. (GUTS) climbed 5.19% to $2.23 after hours, up $0.11, suggesting that its potential in the biotech sector is being recognized by the market.
- Coeptis Therapeutics Increase: Coeptis Therapeutics Holdings, Inc. (COEP) added 4.14% to finish at $13.85, gaining $0.55 in after-hours trading, demonstrating investor support for its strategic direction.
See More
Alto Neuroscience and Others Under Investigation for Shareholder Claims
- Shareholder Lawsuit Investigation: Johnson Fistel, PLLP is investigating shareholder claims against Alto Neuroscience (NYSE: ANRO) and others, alleging breaches of fiduciary duty that could lead to corporate governance reforms and return of funds.
- False Statements Allegations: Alto Neuroscience is accused of making false statements regarding the efficacy of its lead drug ALTO-100, resulting in investor losses when the truth was revealed, negatively impacting the company's reputation and stock price.
- Anticompetitive Pricing Practices: Atkore Inc. (NYSE: ATKR) faces a securities class action lawsuit alleging executives failed to disclose anticompetitive pricing practices related to PVC pipe products, which may lead to legal risks and diminished shareholder trust.
- Safety Risks Concealment: Fly-E Group (NASDAQ: FLYE) is accused of downplaying safety risks associated with its lithium battery technology in electric mobility products, leading to a stock price decline and harming investor interests, affecting the company's future growth prospects.
See More
Alto Neuroscience Secures Patent for ALTO-207, Enhancing Depression Treatment Potential
- Patent Protection Strengthened: Alto has secured U.S. Patent Number 12,521,374 covering methods for treating depression with ALTO-207, which protects the use of ondansetron to mitigate pramipexole-related side effects, enabling patients to achieve higher doses for antidepressant benefits, significantly enhancing ALTO-207's market competitiveness.
- Clinical Trial Success: In a randomized, placebo-controlled Phase 2a clinical trial involving 32 patients with depression, ALTO-207 demonstrated significantly improved MADRS scores, with patients reaching a mean dose of 4.1mg per day, indicating the drug's efficacy and tolerability in treating treatment-resistant depression.
- Intellectual Property Strategy: The issuance of this patent further solidifies Alto's intellectual property portfolio, expected to extend commercial opportunities for ALTO-207 into the mid-2040s, enhancing the company's long-term growth potential in the mental health sector.
- Innovative Treatment Platform: Alto's Precision Psychiatry Platform aims to provide personalized treatment options by analyzing EEG, neurocognitive assessments, and wearable data, driving the company's innovative advancements in depression and other mental health conditions.
See More
Alto Neuroscience Secures Patent for ALTO-207, Protecting Key Treatment Method Until Mid-2040s
- Patent Protection Extended: Alto Neuroscience announced the issuance of U.S. Patent Number 12,521,374 covering methods for treating depression with ALTO-207, expected to provide protection into the mid-2040s, thus offering the company a long-term commercial opportunity in the treatment of treatment-resistant depression.
- Innovative Combination Therapy: ALTO-207 combines pramipexole and ondansetron to mitigate side effects associated with pramipexole, enabling patients to achieve higher doses for more significant antidepressant effects, addressing the urgent market demand for new therapies.
- Clinical Trial Success: In a randomized, placebo-controlled Phase 2a trial involving 32 patients with depression, ALTO-207 demonstrated significant efficacy, with patients reaching a mean dose of 4.1mg per day and an adverse event rate similar to placebo, indicating good tolerability.
- Strategic Value Enhancement: CEO Amit Etkin emphasized that a robust intellectual property foundation is critical for advancing precision treatments, and this patent issuance not only reflects the novelty of ALTO-207 but also strengthens the company's competitive position in the mental health market.
See More
Alto Neuroscience Grants 150,000 Stock Options at $12.80 to New Employee
- Option Grant: On December 2, 2025, Alto Neuroscience granted a new employee an option to purchase 150,000 shares at an exercise price of $12.80, equal to the closing price on the grant date, aimed at attracting talent and enhancing employee loyalty.
- Long-term Incentive Structure: The option has a 10-year term and vests over four years, with 25% vesting on the first anniversary and the remainder in equal monthly installments, ensuring continued employee contribution during their service.
- Compliance Assurance: This grant complies with NYSE Listed Company Manual Rule 303A.08, ensuring the company's adherence to regulations while attracting and retaining key talent with transparency.
- Strategic Implications: By implementing this incentive plan, Alto not only enhances its attractiveness but also demonstrates confidence in future growth, aiming to reshape the field of psychiatry through innovative drug development.
See More
Johnson Fistel, PLLP Launches Investigation for Long-Term Shareholders of Alto Neuroscience, Inc. (ANRO), Atkore Inc. (ATKR), Dow Inc. (DOW), and Fly-E Group, Inc. (FLYE)
Investigation of Shareholder Claims: Johnson Fistel, PLLP is investigating potential claims for shareholders of Alto Neuroscience, Atkore Inc., Dow Inc., and Fly-E Group, Inc. regarding alleged breaches of fiduciary duty by their officers and directors.
Allegations Against Alto Neuroscience: A federal securities class action claims that Alto Neuroscience misrepresented the effectiveness of its drug candidate ALTO-100, leading to investor losses when the truth about its efficacy was revealed.
Concerns with Atkore Inc.: A pending class action alleges that Atkore participated in an anticompetitive price-fixing scheme that inflated prices for PVC pipe products, resulting in financial performance issues once scrutiny increased.
Issues with Dow Inc. and Fly-E Group: Dow is accused of misleading investors about its dividend sustainability amid macroeconomic pressures, while Fly-E faces allegations of downplaying safety issues related to its lithium-battery technology, both leading to significant stock price declines.
See More
